Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients

B. Hoeh, RS. Flammia, L. Hohenhorst, G. Sorce, F. Chierigo, Z. Tian, F. Saad, M. Gallucci, A. Briganti, C. Terrone, SF. Shariat, M. Graefen, D. Tilki, LA. Kluth, P. Mandel, A. Becker, FKH. Chun, PI. Karakiewicz

. 2022 ; 82 (6) : 687-694. [pub] 20220221

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018658

BACKGROUND: The pathological stage of prostate cancer with high-risk prostate-specific antigen (PSA) levels, but otherwise favorable and/or intermediate risk characteristics (clinical T-stage, Gleason Grade group at biopsy [B-GGG]) is unknown. We hypothesized that a considerable proportion of such patients will exhibit clinically meaningful GGG upgrading or non-organ confined (NOC) stage at radical prostatectomy (RP). MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2010-2015) we identified RP-patients with cT1c-stage and B-GGG1, B-GGG2, or B-GGG3 and PSA 20-50 ng/ml. Rates of GGG4 or GGG5 and/or rates of NOC stage (≥ pT3 and/or pN1) were analyzed. Subsequently, separate univariable and multivariable logistic regression models tested for predictors of NOC stage and upgrading at RP. RESULTS: Of 486 assessable patients, 134 (28%) exhibited B-GGG1, 209 (43%) B-GGG2, and 143 (29%) B-GGG3, respectively. The overall upgrading and NOC rates were 11% and 51% for a combined rate of upgrading and/or NOC stage of 53%. In multivariable logistic regression models predicting upgrading, only B-GGG3 was an independent predictor (odds ratio [OR]: 5.29; 95% confidence interval [CI]: 2.21-14.19; p < 0.001). Conversely, 33%-66% (OR: 2.36; 95% CI: 1.42-3.95; p = 0.001) and >66% of positive biopsy cores (OR: 4.85; 95% CI: 2.84-8.42; p < 0.001), as well as B-GGG2 and B-GGG3 were independent predictors for NOC stage (all p ≤ 0.001). CONCLUSIONS: In cT1c-stage patients with high-risk PSA baseline, but low- to intermediate risk B-GGG, the rate of upgrading to GGG4 or GGG5 is low (11%). However, NOC stage is found in the majority (51%) and can be independently predicted with percentage of positive cores at biopsy and B-GGG.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018658
003      
CZ-PrNML
005      
20220804134937.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24313 $2 doi
035    __
$a (PubMed)35188982
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hoeh, Benedikt $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada $1 https://orcid.org/0000000242386584
245    10
$a Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients / $c B. Hoeh, RS. Flammia, L. Hohenhorst, G. Sorce, F. Chierigo, Z. Tian, F. Saad, M. Gallucci, A. Briganti, C. Terrone, SF. Shariat, M. Graefen, D. Tilki, LA. Kluth, P. Mandel, A. Becker, FKH. Chun, PI. Karakiewicz
520    9_
$a BACKGROUND: The pathological stage of prostate cancer with high-risk prostate-specific antigen (PSA) levels, but otherwise favorable and/or intermediate risk characteristics (clinical T-stage, Gleason Grade group at biopsy [B-GGG]) is unknown. We hypothesized that a considerable proportion of such patients will exhibit clinically meaningful GGG upgrading or non-organ confined (NOC) stage at radical prostatectomy (RP). MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2010-2015) we identified RP-patients with cT1c-stage and B-GGG1, B-GGG2, or B-GGG3 and PSA 20-50 ng/ml. Rates of GGG4 or GGG5 and/or rates of NOC stage (≥ pT3 and/or pN1) were analyzed. Subsequently, separate univariable and multivariable logistic regression models tested for predictors of NOC stage and upgrading at RP. RESULTS: Of 486 assessable patients, 134 (28%) exhibited B-GGG1, 209 (43%) B-GGG2, and 143 (29%) B-GGG3, respectively. The overall upgrading and NOC rates were 11% and 51% for a combined rate of upgrading and/or NOC stage of 53%. In multivariable logistic regression models predicting upgrading, only B-GGG3 was an independent predictor (odds ratio [OR]: 5.29; 95% confidence interval [CI]: 2.21-14.19; p < 0.001). Conversely, 33%-66% (OR: 2.36; 95% CI: 1.42-3.95; p = 0.001) and >66% of positive biopsy cores (OR: 4.85; 95% CI: 2.84-8.42; p < 0.001), as well as B-GGG2 and B-GGG3 were independent predictors for NOC stage (all p ≤ 0.001). CONCLUSIONS: In cT1c-stage patients with high-risk PSA baseline, but low- to intermediate risk B-GGG, the rate of upgrading to GGG4 or GGG5 is low (11%). However, NOC stage is found in the majority (51%) and can be independently predicted with percentage of positive cores at biopsy and B-GGG.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a prostata $x patologie $x chirurgie $7 D011467
650    12
$a prostatický specifický antigen $7 D017430
650    _2
$a prostatektomie $x metody $7 D011468
650    12
$a nádory prostaty $x patologie $x chirurgie $7 D011471
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Flammia, Rocco S $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada $u Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy $1 https://orcid.org/0000000231290544
700    1_
$a Hohenhorst, Lukas $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000173688617
700    1_
$a Sorce, Gabriele $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada $u Unit of Urology, Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Chierigo, Francesco $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy $1 https://orcid.org/0000000173570758
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada
700    1_
$a Gallucci, Michele $u Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
700    1_
$a Briganti, Alberto $u Unit of Urology, Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Terrone, Carlo $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York City, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
700    1_
$a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Department of Urology, Koc University Hospital, Istanbul, Turkey $1 https://orcid.org/0000000170331380
700    1_
$a Kluth, Luis A $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Mandel, Philipp $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Becker, Andreas $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Department of Urology, University of Montréal Health Center, Montréal, Canada
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 82, č. 6 (2022), s. 687-694
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35188982 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134930 $b ABA008
999    __
$a ok $b bmc $g 1822329 $s 1169901
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 82 $c 6 $d 687-694 $e 20220221 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace